| Document |
Document Title |
|
WO/2006/100225A2 |
Benzoic acid ester compounds of formula (I) wherein R and R1-R5 have the meanings explained in the description, methods for producing them and use thereof in cosmetic, pharmaceutical, personal care and industrial preparations as sunscree...
|
|
WO/2006/056312A1 |
The invention relates to DOTAP chloride that is devoid of enantiomers, in addition to stable crystalline modifications of (2R,S)-, (2S)- and (2R)-DOTAP chloride. The invention also relates to a method for producing said modifications and...
|
|
WO/2006/040332A1 |
The instant invention relates to the use of compounds derived from the esterification reaction of alkoxylated amines and fatty acids, optionally quaternised with an alkylating agent, and of the cationic surfactants and esterquats obtaina...
|
|
WO/2006/040470A1 |
The invention concerns a method for preparing (meth)acrylic esters or anhydrides from acrylic acid of formulae (I), wherein R is H or Me, and R' is alkyl and R'' is alkyl or ethyl substituted by dialkylamino whereof the alkyls can form w...
|
|
WO/2005/118522A1 |
Disclosed are a monomethylphytosphingosine-polyethyleneglycol (MMPS-PEG) derivative formed by combining monomethylphytosphingosine (MMPS), which is a derivative of sphingolipid, with polyethyleneglycol (PEG) or a pharmaceutically accepta...
|
|
WO/2005/105730A2 |
The invention relates to a method of preparing an alcohol from a halogenoaromatic compound and an aldehyde, leading to an $g(a)-hydroxyalkylaromatic compound. According to the invention, the method of preparing an $g(a)-hydroxyalkylaroma...
|
|
WO/2005/095369A1 |
The present invention relates to water soluble esters of [N-(4-amino-2-butynyl)] or 4-(N-substituted amino)-2-butynyl-1-esters and methods for production of said esters and the use of the esters for treatment of cancer.
|
|
WO/2005/077886A1 |
Novel calcilytic compounds and methods of using them are provided.
|
|
WO/2005/075409A1 |
Ibopamine maleate salt (1: 1), method for preparing it and pharmaceutical composition containing it.
|
|
WO/2005/060603A2 |
The invention describes novel pyruvate compounds comprising at least one nitric oxide releasing group and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one pyruvate compound comprising at least one...
|
|
WO/2005/056516A1 |
The present invention relates to novel compounds corresponding to the general formula (I) below: to compositions containing them and to their use in pharmaceutical compositions intended for use in human or veterinary medicine, or alterna...
|
|
WO/2005/053685A1 |
The present invention relates to β-adrenergic blockers nitrooxyderivatives of general formula (I): A-(Y-ONO2)s, wherein s is an integer equal to 1 or 2; A is selected from the following β-adrenergic blockers residues of formula (II), w...
|
|
WO/2005/049549A1 |
A process for the synthesis of lipid cations having general formula (6) in which: R1 represents a lipophilic chain; R2, R3, R4, which are identical or different from one another, represent C1-C10 alkyl, C1-C10 alkenyl, or C1-C10 alkynyl ...
|
|
WO2004110364A9 |
The current invention provides novel thiotungstate derivatives, methods of making novel thiotungstate derivatives, pharmaceutical compositions of novel thiotungstate derivatives, methods of using novel thiotungstate derivatives to treat ...
|
|
WO/2005/030780A1 |
The present invention relates to a method (assay) for determining the activity of an enzyme selected from the group consisting of a sphingosine kinase and a phosphatase involved in the sphingolipid pathway by use of a labeled sphingosine.
|
|
WO/2005/028457A1 |
The present invention discloses a process for the preparation of quetiapine, which comprises the reaction of dibenzo[b,f][1,4]thiazepin-11-ylamine with a compound of the general formula (II) as well as novel intermediates in the process.
|
|
WO/2005/027157A2 |
A salt fusible at ordinary temperature which comprises: a cation ingredient obtained by introducing a cationic group into a volatile organic solvent; and an anion ingredient selected from the group consisting of an inorganic ion, sulfoni...
|
|
WO/2005/023754A1 |
The invention relates to the preparation of (meth)acrylate di-ammonium salts responding to formula (I) wherein R1 represents hydrogen or methyl, each R2 , independently, represents an alkyl comprising from 1 to 4 carbon atoms, each R3, i...
|
|
WO/2005/021051A1 |
The present invention relates to aminoalkyl substituted fumarates and there use as malodor neutralisers.
|
|
WO/2005/019157A1 |
The present invention provides compounds of formula I described herein. The present invention also provides a method of treating a cognitive dysfunction in a mammal. The method includes administering to the mammal an effective amount of ...
|
|
WO/2005/018631A1 |
This invention comprises a novel class of Choline derivatives for the treatment of Alzheimer’s disease, Down syndrome, Central (or Peripheral) Nervous Systems’ disorders or for the enhancement of memory and central nervous system or ...
|
|
WO/2005/007865A1 |
Optically active &agr -methylcysteine derivative is efficiently produced from an inexpensive raw material. An optically active 2-amino-2-methyl-1,3-propanediol derivative monoester is produced by esterifying one of the hydroxyls of 2-ami...
|
|
WO/2005/007810A2 |
The present invention describes a synthetic non-viral vector composition for gene therapy and the use of such compositions for in vitro, ex vivo and/or in vivo transfer of genetic material. The invention proposes a pharmaceutical composi...
|
|
WO/2004/106278A1 |
The invention provides a process for producing N-alkylaminoalkyl (meth)acrylates reduced in the content of low-boiling components, particularly raw material components without troublesome operation and special equipment, that is, a proce...
|
|
WO2004035523B1 |
The invention provides cationic cardiolipin compounds, and methods for synthesizing and using them in liposomal formulation, gene transfection, etc. In particular, the invention provides liposomes comprising cationic cardiolipin analog, ...
|
|
WO/2004/065349A1 |
The invention relates to the compounds of 1-phenyl-2-aminomethyl naphthalene derivatives of the general formula (1), and to methods for their production. 1-Phenyl-2-aminomethyl naphthalenes have antitumoral properties in cell culture mod...
|
|
WO/2004/060854A1 |
The present invention relates to a process for the minimization of volatile organic sulphur byproducts in dimethyl sulfate quaternization of amines made with hypophosphorous acid, which leads to the formation of an odor stable product.
|
|
WO2004039817A9 |
The invention provides new synthetic routes for cardiolipin with different fatty acids and/or alkyl chains with varying chain length and also with or without unsaturation, particularly a short-chain cardiolipin. The methods comprise reac...
|
|
WO/2004/060363A1 |
The present invention relates to a novel method for producing formulations comprising a polynucleotide, block copolymer and cationic surfactant. The formulations produced by the current method are suitable for use in polynucleotide based...
|
|
WO/2004/058682A1 |
Compounds represented by the general formula (I), salts thereof, and hydrates of both: (I) wherein T is a single bond, optionally substituted C1-4 alkylene, or the like; the symbols &dot &dot &dot &dot &dot &dot are each a single bond or...
|
|
WO/2004/058723A1 |
A fungicidally active compound of formula (I): where Het is a substituted 5- or 6-membered heterocyclic ring; R1 is hydrogen, formyl, CO-C1-4 alkyl, COO-C1-4 alkyl, C1-4 alkoxy(C1-4)alkylene, CO-C1-4 alkylenoxy(C1-4)alkyl, propargyl or a...
|
|
WO/2004/045536A2 |
A method for modifying at least one non-ester-containing parent compound, and the compounds produced using such method, which compounds are deployed to temporarily incapacitate at least one subject are disclosed. The modified compounds a...
|
|
WO/2004/045533A2 |
A method and compositions for treating persistent pulmonary hypertension in human newborns that deploys an intravenous infusion of a modified drug formed by adding one or more of a predetermined chemical arrangement to an efficacious par...
|
|
WO/2004/043921A1 |
A novel, improved, and general process for the preparation of 4-aryl-3-hydroxymethyl-1-methylpiperidines is disclosed in the present invention. 4-(4-Fluorophenyl)-3-hydroxymethyl-1-methylpiperidine is a well-known intermediate in making ...
|
|
WO/2004/039763A1 |
The invention features quaternary ammonium compounds of formula I, described herein, and their use in treating asthma, chronic obstructive pulmonary disorder, allergic rhinitis, and infectious rhinitis.
|
|
WO/2004/029004A1 |
The invention relates to the use of an ionic liquid as a matrix liquid for organic synthesis in a homogeneous phase on a soluble medium, said ionic liquid being present in the form of a liquid or solid at room temperature, having formula...
|
|
WO/2004/026817A1 |
An amino alcohol derivative represented by the general formula (1): (1) &lcub e.g., (±)-2-amino-5-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-2-
methylpentan-1-ol&rcub . It has excellent immunosuppressive activity and is reduced in side ...
|
|
WO/2004/027789A1 |
The use of a composition for polyelectrolytes comprising a quaternary ammonium salt (A) represented by the general formula (1) and an inonic fluid (B) brings about polyelectrolytes which retain excellent characteristics inherent in the i...
|
|
WO/2004/016579A1 |
The invention relates to a method for producing 3-amino-4,4,4-trifluorocrotonic acid esters of formula (I) or their E/Z isomers or tautomeric forms, whereby R1 and R2, independent of one another, represent hydrogen, an optionally substit...
|
|
WO/2004/013086A1 |
Diamine compounds, which in particular are useful as precursors for the production of liquid crystal alignment layers, represented by general formula (I), wherein A1 represents an organic group of 1 to 40 carbon atoms; A2 represents a hy...
|
|
WO/2004/013083A1 |
Nolomirole hydrochloride in a highly purified crystalline polymorphic form I, the process for its preparation and pharmaceutical preparations thereof for the treatment of patients suffering of cardiovascular diseases such as congestive h...
|
|
WO/2004/009034A2 |
The current invention provides novel thiomolybdate derivatives, methods of making novel thiomolybdate derivatives, pharmaceutical compositions of novel thiomolybdate derivatives, methods of using novel thiomolybdate derivatives to treat ...
|
|
WO/2004/004648A2 |
The invention describes novel nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound ...
|
|
WO/2004/003102A2 |
The invention relates to new polymerizable, luminescent compounds of formula I wherein R1, R2, Q and L1 have the meanings given in claim 1. Furthermore the invention relates to polymerizable mixtures containing compounds according to the...
|
|
WO/2003/104178A1 |
Where Y, R¿1?-R¿8? and R¿101?-R¿108? are as defined in the specification. Compounds of formula (II) and methods of inhibiting the cytokine or biological activity of Macrophage Migrating Inhibitory Factor (MIF) comprising contacting M...
|
|
WO/2003/103650A1 |
The invention relates to active ingredient salts and esters of 1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol and 3-(3-dimethylamino-1-ethyl-1-hydroxy-2-methyl-propyl)-phenol
, to methods for the production thereof, and to the...
|
|
WO/2003/099769A1 |
The present invention is directed to selective LXR modulators, small molecule compounds corresponding to Formula I and is further directed to a process of treating a condition in a mammal that is modulated by LXR using a therapeutically ...
|
|
WO/2003/093218A1 |
The invention concerns a method for making dimethylaminoethyl acrylate by transesterification from dimethylaminoethanol and ethyl acrylate in the presence of a transesterification catalyst and at least one polymerisation inhibitor, the a...
|
|
WO/2003/091204A1 |
The present invention relates to novel compounds of formula (I), or a salt, solvate, or physiologically functional derivative thereof, to a process for their manufacture, to pharmaceutical compositions containing them, and to their use i...
|
|
WO/2003/088915A2 |
The present invention is directed to novel phenytoin derivative compounds and the use of such compounds as sodium channel blockers. Such compositions have utility as anti-cancer agents and can be used to limit or prevent PCa growth and/o...
|
